Interní Med. 2016; 18(3): 114-119 | DOI: 10.36290/int.2016.028

Current view of the pharmacotherapy of COPD

doc. MUDr. Norbert Pauk, Ph.D.
Klinika pneumologie a hrudní chirurgie Nemocnice Na Bulovce, 3. LF UK a IPVZ Praha

In Europe, the prevalence ranges from 4 % to 10 % in persons over 40 yearsof age. However, the condition is largely underdiagnosed

and the number of patients is expected to be two-fold and the prevalence hasbeen steadily increasing, particularly among

women. Modern pharmacotherapy can affect numerous parameters, improves the quality

of life of patients, alleviates the symptoms, reduces exacerbations and appears to positively affect the disease-related mortality.

Keywords: COPD, pharmacotherapy, dual bronchodilatation, COPD phenotypes

Published: July 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pauk N. Current view of the pharmacotherapy of COPD. Interní Med. 2016;18(3):114-119. doi: 10.36290/int.2016.028.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3(11): e442. Go to original source... Go to PubMed...
    2. Global strategy for diagnosis, management and prevention of chronic pulmonary disease. GOLD Report, Revised 2016. Available from www.goldcopd.org
    3. Kašák V. CHOPN v České republice v roce 2013. Postgrad Med, 2013; 15: 321-335.
    4. In Kolek V, Kašák V, Vašáková M, et al. Pneumologie. 2. vyd. Praha : Maxdorf 2014: 126-156. 10. G
    5. Koblížek V, Chlumský J, Zindr V, et al. Doporučený postup ČPFS pro diagnostiku a léčbu stabilní CHOPN. Praha: Maxdorf Jessenius, 2013: 134.
    6. Miravitlles M, Soler-Cataluna JJ, Calle M, et al. Spanish Guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol 2014; 50(Suppl 1): 1-16. Go to original source...
    7. Koblížek V, et al. Chronic Obstructive Pulmonary Disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2013; 157: 189-201. Go to original source... Go to PubMed...
    8. Woodruff PG, Agustí A, Roche N, et al. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet 2015; 385: 1789-98. Go to original source...
    9. Beeh KM, Beier J. The Short, the Long, and the "Ultra-long": Why Duration of Bronchodilator Action Matters in Chronic Obstructive Pulmonary Disease. Adv Ther 2010;27:150-159. Go to original source... Go to PubMed...
    10. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010; 11: 149. Go to original source... Go to PubMed...
    11. Kašák V. Indacaterol/glykopyrronium bromid - první fixní kombinace s dlouhodobým duálním bronchodilatačním účinkem v léčbě CHOPN. Farmakoterapie, 2014; 10: 436-447.
    12. Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012; 67: 781-788. Go to original source...
    13. Van Noord JA, Aumann JL, Janssens, et al. Effects of tiotropium with and without formoterol on airflow obstruction an resting hyperinflation in patients with COPD. Chest 2006; 129: 509-517. Go to original source... Go to PubMed...
    14. D'Urzo A, Kerwin E, Rennard S, et al. One year extension study of ACCORD COPD: safety and efficacy of two doses of twice daily aclidinium bromide in patients with COPD. COPD 2013; 10: 500-510. Go to original source...
    15. Roffel AF, Meurs H, Zaagsma J. Identification, localization and function of muscarinic receptor subtypes in the airways. Muscarinic Receptors in Airways Diseases. Springer Basel, Switzerland, 2001: 63-85. Go to original source...
    16. Norman P. Long-acting muscarinic M3 receptor antagonists. Expert Opin Ther Pat. 2006; 16: 1315-1320. Go to original source... Go to PubMed...
    17. Woods JA, Nealy KL, Barrons RW. Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease. Ann Pharmacother 2013; 47: 1017-1028. Go to original source... Go to PubMed...
    18. Domínguez-Fandos D, Ferrer E, Puig-Pey R, et al. Effects of aclidinium bromide in a cigarette smoke-exposed guinea pig model of chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2014; 50: 337-346. Go to original source...
    19. Johnson M. The ?2-adrenoceptor. Am J Respir Crit Care Med 1998; 158: 146-153. Go to original source...
    20. Barnes PJ. Distribution of receptor targets in the lungs. Proc Am Thorac Soc 2004; 1: 345-51. Go to original source... Go to PubMed...
    21. Cazzola M, Page C. Long-acting bronchodilators in COPD: where are we now and where are we going? Breathe 2014; 10: 110-120. Go to original source...
    22. Cazzola M, Rogliani P, Matera MG. Aclidinium bromide/formoterol fumarate fixed dose combination for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacoter 2014; 14: 775-781. Go to original source...
    23. Buhl R, Banerji D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J COPD 2012; 7: 729-741. Go to original source... Go to PubMed...
    24. Jones PW, Mahler DA, Gale R, et al. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir Med 2011; 105: 892-899. Go to original source... Go to PubMed...
    25. Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharm Ther 2012; 26: 256-264. Go to original source...
    26. Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat(R) versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J COPD 2014; 9: 697-714. Go to original source...
    27. Trivedi R, Richard N, Mehta R, et al. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J 2014; 43: 72-81. Go to original source... Go to PubMed...
    28. Donohue JF, Singh D, Munzu C, et al. Evaluating lung function response to umeclidinium/vilanterol (UMEC/VI) 62.5/25mcg, UMEC 62.5mcg and VI 25mcg in COPD patients. Eur Respir J 2014; 44(Suppl 58): P291.
    29. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J 2015; 45: 869-871. Go to original source... Go to PubMed...
    30. Celli B, Crater G, Kilbride S, et al. Once-Daily Umeclidinium/Vilanterol 125/25 ug Therapy in COPD. A Randomized, Controlled Study. Chest 2014; 145: 981-991. Go to original source... Go to PubMed...
    31. D'Urzo A, Rennard SI, Kerwin E, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomised, placebo-controlled AUGMENT-COPD study. Respir Res 2014; 15: 123-141. Go to original source... Go to PubMed...
    32. Kašák V. Inhalační systémy v terapii astmatu a chronické obstrukční plicní nemoci. Remedia, 2014; 24: 315-320. 20
    33. Turčáni P. Roflumilast a CHOPN. Klin Farmakol Farm 203; 27(1): 30-37.
    34. Wedzicha JA, Rabe KF, Martinez FJ, et al. Efficacy of Roflumilast in the COPD Frequent Exacerbator Phenotype. Chest 2013; 143: 1302-1311. Go to original source... Go to PubMed...
    35. Diagnosis of diseases of chronic airflow limitation: Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS). GINA 2014, GOLD 2014. Dostupné na www.ginasthma.org.
    36. Decramer, M., Cooper, CB. Treatment of COPD: the sooner the better. Thorax, 2010; 65: 837-841. Go to original source...
    37. Agustí A. The path to personalised medicine in COPD. Thorax 2014; 69: 857-864. Go to original source...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.